Read this company snapshot
Daily valuation snapshot
CG Oncology, Inc. Common stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $63.82
- Market capitalization (USD)
- $5,657,028,732.5
- Price / earnings (TTM)
- Not reported
- Price / book
- 5.5
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CGON in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research CGON in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing CGON with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $63.82 |
| Market capitalization (USD) | $5,657,028,732.5 |
| Price / earnings (TTM) | Not reported |
| Price / book | 5.5 |
No matching rows. Clear the filter to see all records.
Read CGON's valuation metrics
Company size
CG Oncology, Inc. Common stock's recorded market capitalization is $5,657,028,732.5. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
CGON's recorded price-to-book ratio is 5.5. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research CG Oncology, Inc. Common stock with Aurora
Use the snapshot above to ask a specific question about CGON. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow CGON's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.